🌱 created from: hepatocellular carcinoma

systemic_therapies-of-hepatocellular_carcinoma

Summary of Clinical Trials for Liver Cancer Treatments

• Atezolizumab/Bevacizumab vs. Sorafenib

  • Atezolizumab/Bevacizumab (C-P Class A only) improves OS vs. sorafenib (median OS 19.2 vs. 13.4 mos)
    • Ref: IMbrave 150, NEJM 2020;382:1894; JCO 2021; 39(3_suppl):267
  • Evaluate & treat esophageal varices before initiating treatment
  • OS benefit seen in antidrug antibody (ADA) negative patients but not ADA positive patients
    • Ref: Cancer Research 2021;81(13_suppl):CT185

• Sorafenib vs. Placebo

  • Sorafenib (C-P Class A only) improves OS vs. placebo (median OS 10.7 vs. 7.9 mos)
    • Ref: SHAPR, NEJM 2008;359:378; Lancet Oncol 2009;10:25
  • May be considered for C-P class B7

• Lenvatinib vs. Sorafenib

  • Lenvatinib (C-P Class A only) is noninferior to sorafenib (median OS 13.6 vs. 12.3 mos)
    • Ref: REFLECT, Lancet 2018:391:1163

Treatment	Median OS (months)	Reference(s)
Atezolizumab/Bevacizumab	19.2	IMbrave 150, NEJM 2020; JCO 2021
Sorafenib	13.4	Cancer Research 2021
Sorafenib (vs. Placebo)	10.7	SHAPR, NEJM 2008; Lancet Oncol 2009
Lenvatinib	12.3	REFLECT, Lancet 2018